BAKER BROS. ADVISORS LP Q3 2022 Filing
Filed November 14, 2022
Portfolio Value
$15.3B
Holdings
115
Report Date
Q3 2022
Filing Type
13F-HR
All Holdings (115 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | 46,912,266 | $6.4T | 42038.23% | |
| 2 | INCYIncyte Corporation | 36,154,574 | $2.4T | 15778.84% | |
| 3 | ONCBeiGene, Ltd. | 11,668,897 | $1.6T | 10302.93% | |
| 4 | ACADACADIA Pharmaceuticals Inc. | 41,923,486 | $685.9B | 4491.77% | |
| 5 | BMRNBioMarin Pharmaceutical Inc. | 7,620,494 | $646.0B | 4230.60% | |
| 6 | ASNDAscendis Pharma A/S | 4,852,655 | $501.1B | 3281.62% | |
| 7 | GBTUSDGlobal Blood Therapeutics, Inc. | 3,732,502 | $254.2B | 1664.65% | |
| 8 | BCRXBioCryst Pharmaceuticals, Inc. | 12,710,818 | $160.2B | 1048.87% | |
| 9 | RYTMRhythm Pharmaceuticals, Inc. | 6,062,702 | $148.5B | 972.77% | |
| 10 | KODKodiak Sciences Inc. | 17,310,490 | $134.0B | 877.46% | |
| 11 | IMCRImmunocore Holdings plc | 2,520,731 | $118.3B | 774.90% | |
| 12 | ABCLAbCellera Biologics Inc. | 10,450,180 | $103.4B | 676.85% | |
| 13 | ARGXargenx SE | 280,159 | $98.9B | 647.76% | |
| 14 | MRTXEURMirati Therapeutics, Inc. | 1,409,784 | $98.5B | 644.81% | |
| 15 | MDGLMadrigal Pharmaceuticals, Inc. | 1,499,213 | $97.4B | 638.10% | |
| 16 | CCXIEURChemoCentryx, Inc. | 1,792,657 | $92.6B | 606.50% | |
| 17 | TVTXTravere Therapeutics, Inc. | 3,300,009 | $81.3B | 532.51% | |
| 18 | AKROAkero Therapeutics, Inc. | 2,368,378 | $80.6B | 528.13% | |
| 19 | TRDAEntrada Therapeutics, Inc. | 4,865,819 | $76.7B | 502.21% | |
| 20 | 1K0IGM Biosciences, Inc. | 3,156,102 | $71.8B | 470.02% | |
| 21 | REPLReplimune Group, Inc. | 3,893,843 | $67.2B | 440.40% | |
| 22 | PRLDPrelude Therapeutics Inc. | 10,123,824 | $66.9B | 438.25% | |
| 23 | KYMRKymera Therapeutics, Inc. | 2,879,825 | $62.7B | 410.58% | |
| 24 | HZNPHorizon Therapeutics Public Ltd Co | 969,727 | $60.0B | 393.05% | |
| 25 | CERSCerus Corporation | 16,067,558 | $57.8B | 378.82% | |
| 26 | NRIXNurix Therapeutics, Inc. | 3,882,125 | $50.6B | 331.28% | |
| 27 | 290AChinook Therapeutics, Inc. | 2,534,102 | $49.8B | 326.27% | |
| 28 | VERVVerve Therapeutics, Inc. | 1,416,530 | $48.7B | 318.66% | |
| 29 | IMTXImmatics N.V. | 4,423,731 | $44.2B | 289.71% | |
| 30 | —Forma Therapeutics Holdings, Inc. | 1,886,760 | $37.6B | 246.51% | |
| 31 | INSM 0.75 06/01/28Insmed Incorporated | 40,000,000 | $36.3B | 237.70% | |
| 32 | KNSAKiniksa Pharmaceuticals, Ltd. | 2,799,577 | $35.9B | 235.42% | |
| 33 | HRTXHeron Therapeutics, Inc. | 8,131,678 | $34.3B | 224.74% | |
| 34 | AVTEAerovate Therapeutics, Inc. | 1,979,568 | $32.8B | 214.95% | |
| 35 | TSVT*2seventy bio, Inc. | 2,062,744 | $30.0B | 196.56% | |
| 36 | KRYSKrystal Biotech, Inc. | 422,185 | $29.4B | 192.71% | |
| 37 | XENEXenon Pharmaceuticals Inc. | 751,639 | $27.1B | 177.70% | |
| 38 | —CinCor Pharma, Inc. | 807,212 | $26.5B | 173.50% | |
| 39 | —DBV Technologies S.A. | 14,614,264 | $25.9B | 169.40% | |
| 40 | IDYAIDEAYA Biosciences, Inc. | 1,668,355 | $24.9B | 163.02% | |
| 41 | DSGNDesign Therapeutics, Inc. | 1,436,636 | $24.0B | 157.31% | |
| 42 | VSTMVerastem, Inc. | 26,988,898 | $22.9B | 150.24% | |
| 43 | ALTAltimmune, Inc. | 1,769,681 | $22.6B | 148.00% | |
| 44 | NVTA1EURInvitae Corporation | 8,402,035 | $20.7B | 135.36% | |
| 45 | BMEABiomea Fusion, Inc. | 2,104,559 | $20.6B | 134.80% | |
| 46 | BCYCBicycle Therapeutics plc | 843,814 | $19.6B | 128.54% | |
| 47 | RAREUltragenyx Pharmaceutical Inc. | 470,974 | $19.5B | 127.73% | |
| 48 | TILInstil Bio, Inc. | 3,893,700 | $18.8B | 123.42% | |
| 49 | VERUEURVeru Inc. | 1,609,579 | $18.5B | 121.43% | |
| 50 | RLMDRelmada Therapeutics, Inc. | 495,113 | $18.3B | 120.04% | |
| 51 | ALKSAlkermes plc | 815,016 | $18.2B | 119.19% | |
| 52 | DNLIDenali Therapeutics Inc. | 588,738 | $18.1B | 118.33% | |
| 53 | OPTEYOpthea Limited | 2,691,391 | $16.7B | 109.28% | |
| 54 | —bluebird bio, Inc. | 2,499,715 | $15.8B | 103.63% | |
| 55 | CRNXCrinetics Pharmaceuticals, Inc. | 735,716 | $14.4B | 94.63% | |
| 56 | WHWKAadi Bioscience, Inc. | 989,928 | $14.0B | 91.61% | |
| 57 | 1T7Tricida, Inc. | 1,320,290 | $13.8B | 90.62% | |
| 58 | —Affimed N.V. | 6,596,830 | $13.6B | 88.99% | |
| 59 | —DICE Therapeutics, Inc. | 588,235 | $11.9B | 78.12% | |
| 60 | ANABAnaptysBio, Inc. | 427,179 | $10.9B | 71.36% | |
| 61 | FGENEURFibroGen, Inc. | 815,718 | $10.6B | 69.50% | |
| 62 | ADAPYAdaptimmune Therapeutics plc | 9,830,877 | $10.6B | 69.21% | |
| 63 | —Zymeworks Inc. | 1,708,472 | $10.5B | 68.81% | |
| 64 | —POINT Biopharma Global Inc. | 1,169,103 | $9.0B | 59.18% | |
| 65 | TCRXTScan Therapeutics, Inc. | 2,784,792 | $8.5B | 55.63% | |
| 66 | —Invitae Corporation | 10,300,000 | $8.1B | 53.36% | |
| 67 | CBAYUSDCymaBay Therapeutics, Inc. | 2,170,464 | $7.6B | 49.75% | |
| 68 | VERAVera Therapeutics, Inc. | 333,333 | $7.1B | 46.52% | |
| 69 | PACBPacific Biosciences of California, Inc. | 1,127,782 | $6.5B | 42.88% | |
| 70 | FLGTFulgent Genetics, Inc. | 166,619 | $6.4B | 41.60% | |
| 71 | AMRNAmarin Corporation plc | 5,377,113 | $5.9B | 38.38% | |
| 72 | 698Achilles Therapeutics plc | 2,591,366 | $5.9B | 38.35% | |
| 73 | VORVor Biopharma Inc. | 1,465,925 | $5.8B | 38.21% | |
| 74 | RETAEURReata Pharmaceuticals, Inc. | 223,976 | $5.6B | 36.86% | |
| 75 | BCELAtreca, Inc. | 3,532,760 | $5.5B | 36.32% | |
| 76 | NKTXNkarta, Inc. | 400,000 | $5.3B | 34.47% | |
| 77 | —Talis Biomedical Corporation | 7,624,835 | $5.2B | 34.04% | |
| 78 | KRON1USDKronos Bio, Inc. | 1,539,616 | $5.2B | 33.78% | |
| 79 | CYTCyteir Therapeutics, Inc. | 2,643,640 | $5.1B | 33.24% | |
| 80 | SRZNSurrozen, Inc. | 2,500,000 | $5.0B | 33.07% | |
| 81 | EWTXEdgewise Therapeutics, Inc. | 500,000 | $4.9B | 32.22% | |
| 82 | FATEFate Therapeutics, Inc. | 215,695 | $4.8B | 31.66% | |
| 83 | STOKStoke Therapeutics, Inc. | 369,327 | $4.7B | 31.06% | |
| 84 | RVMDRevolution Medicines, Inc. | 222,222 | $4.4B | 28.70% | |
| 85 | NTRANatera, Inc. | 100,000 | $4.4B | 28.70% | |
| 86 | ALLKGUSDAllakos Inc. | 703,050 | $4.3B | 28.18% | |
| 87 | CLDNEUREiger BioPharmaceuticals, Inc. | 539,851 | $4.1B | 26.62% | |
| 88 | PMVPPMV Pharmaceuticals, Inc. | 322,024 | $3.8B | 25.10% | |
| 89 | IPSCCentury Therapeutics, Inc. | 370,587 | $3.7B | 24.00% | |
| 90 | HOOKGBPHOOKIPA Pharma Inc. | 2,400,481 | $3.2B | 21.07% | |
| 91 | —Athira Pharma, Inc. | 1,040,834 | $3.1B | 20.24% | |
| 92 | MGNXMacroGenics, Inc. | 892,579 | $3.1B | 20.22% | |
| 93 | 5E7iTeos Therapeutics, Inc. | 150,346 | $2.9B | 18.76% | |
| 94 | ATRAGBXAtara Biotherapeutics, Inc. | 744,186 | $2.8B | 18.42% | |
| 95 | TNGXTango Therapeutics, Inc. | 750,000 | $2.7B | 17.78% | |
| 96 | SNDXSyndax Pharmaceuticals, Inc. | 110,729 | $2.7B | 17.43% | |
| 97 | OTICEUROtonomy, Inc. | 8,443,134 | $2.5B | 16.31% | |
| 98 | —Neoleukin Therapeutics, Inc. | 3,821,740 | $2.4B | 16.02% | |
| 99 | ALGSAligos Therapeutics, Inc. | 2,076,400 | $2.3B | 14.96% | |
| 100 | ALECAlector, Inc. | 239,228 | $2.3B | 14.82% |
Page 1 of 2Next